BioXcel Therapeutics, Inc.

NASDAQ:BTAI

1.18 (USD) • At close May 30, 2025
Bedrijfsnaam BioXcel Therapeutics, Inc.
Symbool BTAI
Munteenheid USD
Prijs 1.18
Beurswaarde 7,146,139
Dividendpercentage 0%
52-weken bereik 1.17 - 30.88
Industrie Biotechnology
Sector Healthcare
CEO Dr. Vimal D. Mehta Ph.D.
Website https://www.bioxceltherapeutics.com

An error occurred while fetching data.

Over BioXcel Therapeutics, Inc.

BioXcel Therapeutics, Inc. is a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. Its commercial

Vergelijkbare Aandelen

Fulcrum Therapeutics, Inc. logo

Fulcrum Therapeutics, Inc.

FULC

6.875 USD

Heron Therapeutics, Inc. logo

Heron Therapeutics, Inc.

HRTX

1.88 USD

HilleVax, Inc. logo

HilleVax, Inc.

HLVX

1.87 USD

Absci Corporation logo

Absci Corporation

ABSI

2.65 USD

ALX Oncology Holdings Inc. logo

ALX Oncology Holdings Inc.

ALXO

0.486 USD

Athira Pharma, Inc. logo

Athira Pharma, Inc.

ATHA

0.313 USD

C4 Therapeutics, Inc. logo

C4 Therapeutics, Inc.

CCCC

1.25 USD

OraSure Technologies, Inc. logo

OraSure Technologies, Inc.

OSUR

2.88 USD

EyePoint Pharmaceuticals, Inc. logo

EyePoint Pharmaceuticals, Inc.

EYPT

7.24 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)